Pertussis-only vaccine, designed for today’s needs

As we’ve discussed, traditional pertussis vaccines have some limitations, particularly when it comes to how long they can protect you. But here’s where things get exciting: there’s a new way to fight pertussis that’s designed to overcome these challenges—introducing the Recombinant Pertussis Vaccine (RPV).  Unlike the traditional Tdap vaccines, RPV uses genetically detoxified technology. What does that mean? It means the vaccine can keep the important parts of the pertussis bacteria intact, allowing your immune system to generate strong and long-lasting protection against whooping cough.1, 4-12 With RPV, we’re taking a major step forward in the fight against pertussis, offering protection that’s built for today’s needs.11-12

Long-lasting immunity
aP uses advanced technology that demonstrated its effectiveness and safety as an alternative to traditional Tdap vaccines.4-13 

Fewer side effects
Since it only contains the pertussis component, aP reduces the likelihood of reactions that sometimes occur with Tdap combination vaccines. 

Flexibility
Whether you’re pregnant, have had multiple doses of other vaccines, or need to catch up on your shots, aP offers a focused solution to protect against whooping cough. 

Tailored solutions for Pertussis vaccine throughout life

Booster vaccination

Preteens /teens

Adults

Elderly *

Travelers **

* If not given during adulthood

** Up to date vaccination

Infant protection

Pregnant women *

Postpartum **

Family ***

Healthcare personnel


* Each pregnancy

*** In close contact with newborn

** If not given during pregnancy

References

  1. Ibsen PH, The effect of formaldehyde, hydrogen peroxide and genetic detoxification of pertussis toxin on epitope recognition by murine monoclonal antibodies, Vaccine, Volume 14, Issue 5, 1996, Pages 359-368 
  1. Acosta AM, et al. Tdap vaccine effectiveness in adolescents during the 2012 Washington State pertussis epidemic. Pediatrics. 2015 Jun;135(6):981-9 
  1. Klein NP, et al. Waning Tdap Effectiveness in Adolescents. Pediatrics. 2016 Mar;137(3):e20153326 
  1. Sricharoenchai S, et al. A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial The Lancet Infectious Diseases, Volume 18, Issue 1, 58 – 67 
  1. Pitisuttithum P, et al. Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdaPgen vaccines. EClinicalMedicine. 2021 Jun 23;37:100976 
  1. Chokephaibulkit K, et al. A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age, Vaccine, Volume 40, Issue 15, 2022, Pages 2352-2361 
  1. Puthanakit T, et al. A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant women, Vaccine, Volume 41, Issue 31, 2023, Pages 4541-4553 
  1. Chokephaibulkit K, et al. Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing vaccines, Vaccine, Volume 42, Issue 2, 2024, Pages 383-395 
  1. Chaithongwongwatthana S, et al. Transplacental transfer of maternal antibodies following immunization with recombinant pertussis vaccines during pregnancy: Real-world evidence, Int J Infect Dis. 2024 Jul;144:107047.  
  1. Blanchard RG, et al. Boosting Teenagers With Acellular Pertussis Vaccines Containing Recombinant or Chemically Inactivated Pertussis Toxin: A Randomized Clinical Trial. Clin Infect Dis. 2019 Mar 19;68(7):1213-1222 
  1. Gregg KA, Merkel TJ. Pertussis Toxin: A Key Component in Pertussis Vaccines? Toxins (Basel). 2019 Sep 21;11(10):557 
  1. McIntyre P, et al. Genetically modified pertussis toxin: a quantum leap? The Lancet Infectious Diseases, Volume 18, Issue 11, 1169 – 1171 
  1. Heininger U. Diphtheria, Tetanus, and Pertussis: Unequal Vaccine Siblings With Distinct Characteristics. Clin Infect Dis. 2022 Feb 11;74(3):562-563. 
  1. Safety of Immunization during Pregnancy: A review of the evidence, Global Advisory Committee on Vaccine Safety, World Health Organization 2014 
  1. Selley P. Vaccine manufacturers should produce a pertussis only vaccine for use in pregnancy. BMJ 2024;386:q1669 
  1. Advisory Committee on Immunization Practices (ACIP) Summary Report October 24-25, 2018 Atlanta, Georgia